<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3663">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04392973</url>
  </required_header>
  <id_info>
    <org_study_id>RC20/174</org_study_id>
    <nct_id>NCT04392973</nct_id>
  </id_info>
  <brief_title>FAvipiravir and HydroxyChloroquine Combination Therapy</brief_title>
  <acronym>FACCT</acronym>
  <official_title>A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Abdullah International Medical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Abdullah International Medical Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, open-label, parallel groups multi-centered trial were&#xD;
      participants are assigned to either an intervention arm ( a combination of Favipiravir and&#xD;
      Hydroxychloroquin) or standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this trial, the investigators want to evaluate the efficacy of the combination of&#xD;
      Favipiravir and Hydroxychloroquine as potential therapy for moderate and severe cases with&#xD;
      COVID -19. Favipiravir which is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor&#xD;
      has activity against influenza virus, and Hydroxychloroquine, an analogue of chloroquine, has&#xD;
      a clinical safety profile better than that of chloroquine and allows higher daily dose,&#xD;
      Chloroquine is a widely used antimalarial that was found to be a potential broad-spectrum&#xD;
      antiviral.&#xD;
&#xD;
      There is an urgent need to explore therapeutic options for SARS-CoV-2 in order to face the&#xD;
      pandemic. The selected combination was based on limited evidence clinically and in vitro on&#xD;
      the efficacy of the Favipiravir and Hydroxychloroquine in SARS-CoV-2. The two medications&#xD;
      were listed in many guidelines as treatment options and ongoing trials assessing their&#xD;
      efficacy and safety. Thus, the investigators want to prove the effectiveness of the&#xD;
      combination as therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, open-label, parallel groups were participants are assigned to either an intervention arm or standard of care.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Improvement</measure>
    <time_frame>28 days</time_frame>
    <description>The primary endpoint is the time to clinical improvement, defined as the time from the randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever came first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral shedding</measure>
    <time_frame>28 days</time_frame>
    <description>PCR test negative conversion days from positive to negative.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>COVID19</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy Favipiravir (10 days) + Hydroxychloroquine(5 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care Treatment for COVID-19 Infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Favipiravir and Hydroxychloroquine</intervention_name>
    <description>Route of Administration: Oral (or through Nasogastric tube)&#xD;
Dose:&#xD;
Favipiravir: Administer 1800 mg (9 tablets) by mouth twice daily for one day, followed by 800mg (4 tablets) twice daily (total days of therapy is 10 days or till hospital discharge)&#xD;
Hydroxychloroquine (400mg) twice daily on day 1; for days 2-5 (200mg) twice daily.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Avigan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Should be at least 18 years of age&#xD;
&#xD;
          2. Male or nonpregnant female,&#xD;
&#xD;
          3. Diagnosed with COVID-19 by PCR confirmed SARS-coV-2 viral infection.&#xD;
&#xD;
          4. Able to sign the consent form and agree to clinical samples collection (or their legal&#xD;
             surrogates if subjects are or become unable to make informed decisions).&#xD;
&#xD;
          5. Moderate or Severe COVID-19, defined as oxygen saturation (Sao2) of 94% or less while&#xD;
             they were breathing ambient air or significant clinical symptoms with Chest X ray&#xD;
             changes that require hospital admission.&#xD;
&#xD;
          6. patients had to be enrolled within 10 days of disease onset&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are pregnant or breastfeeding.&#xD;
&#xD;
          2. Will be transferred to a non-study site hospital or expected to be discharged within&#xD;
             72 hours.&#xD;
&#xD;
          3. Known sensitivity/allergy to hydroxychloroquine or Favipiravir&#xD;
&#xD;
          4. Current use of hydroxychloroquine for another indication&#xD;
&#xD;
          5. Prior diagnosis of retinopathy&#xD;
&#xD;
          6. Prior diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency&#xD;
&#xD;
          7. Major comorbidities increasing the risk of study drug including: i. Hematologic&#xD;
             malignancy, ii. Advanced (stage 4-5) chronic kidney disease or dialysis therapy, iii.&#xD;
             Known history of ventricular arrhythmias, iv. Current use of drugs that prolong the QT&#xD;
             interval, Severe liver damage (Child-Pugh score ≥ C, AST&gt; 5 times the upper limit),&#xD;
             HIV.&#xD;
&#xD;
          8. The investigator believes that participating in the trial is not in the best interests&#xD;
             of the patient, or the investigator considers unsuitable for enrollment (such as&#xD;
             unpredictable risks or subject compliance issues).&#xD;
&#xD;
          9. Clinical prognostic non-survival, palliative care, or in deep coma and no have&#xD;
             response to supportive treatment within three hours of admission.&#xD;
&#xD;
         10. Patient with irregular rhythm&#xD;
&#xD;
         11. Patient with a history of heart attack (myocardial infarction)&#xD;
&#xD;
         12. Patient with a family history of sudden death from heart attack before the age of 50&#xD;
&#xD;
         13. Take other drugs that can cause prolonged QT interval&#xD;
&#xD;
         14. Patient who is receiving immunosuppressive therapy (cyclosporin) which cannot be&#xD;
             switched to another agent or adjusted while using the investigational drug&#xD;
&#xD;
         15. Gout/history of Gout or hyperuricemia (above the ULN), hereditary xanthinuria or&#xD;
             xanthine calculi of the urinary tract.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad Alaskar</last_name>
    <role>Study Director</role>
    <affiliation>KAIMRC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammad Bosaeed</last_name>
    <phone>+966(11)8011111</phone>
    <email>dr.bosaeed@live.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Majed Al Jeraisy</last_name>
    <phone>+96611 8494455</phone>
    <phone_ext>94455</phone_ext>
    <email>JeraisyM@NGHA.MED.SA</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>King Abdulaziz Hospital - Al Ahsa</name>
      <address>
        <city>Hasa</city>
        <state>Eastern Region</state>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdulmajeed Alarfaj</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AlMadina General Hospital</name>
      <address>
        <city>Al Madīnah</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khalid Ghalilah</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Al-Qatif Central Hospital</name>
      <address>
        <city>Al-Qatif</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jumana Al Jishi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imam Abdulrahman Al Faisal Hospital - Dammam</name>
      <address>
        <city>Dammam</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abdulatif Alarfaj</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Abdulaziz Medical City</name>
      <address>
        <city>Jeddah</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hadeel AlTayib</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Abdulaziz Hospital - Makkah</name>
      <address>
        <city>Mecca</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faisal Alharbi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Abdulaziz Medical City, National Guard Health Affairs</name>
      <address>
        <city>Riyadh</city>
        <zip>11426</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Bosaeed, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imam Abdulrahman Alfaisal Hospital</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 10, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>July 26, 2020</last_update_submitted>
  <last_update_submitted_qc>July 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

